Protagonist Therapeutics, Inc (PTGX): Results of Operations and Financial Condition
Protagonist Therapeutics, Inc (PTGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phas
How this was made
The 30-second read
Why it matters
Traders can reprice probability-weighted outcomes for rusfertide ahead of the August 2026 PDUFA decision, while also monitoring ICOTYDE’s early commercial adoption and the timing of pipeline starts in early 2027.
Market read
Primary-source disclosure of a near-term FDA decision timeline (Priority Review, PDUFA in August 2026) plus first full quarter of ICOTYDE commercial sales and updated cash position.
What to watch
The filing emphasizes milestone and royalty economics from opt-out and collaboration, but it does not provide detailed guidance or full income statement drivers beyond the reported quarter.
Protagonist reported second-quarter net income of $162,849 (in thousands), supported primarily by proportional recognition of Takeda's opt-out payment, while advancing ICOTYDE commercialization and wholly owned pipeline programs.
License and collaboration revenue rose to $213,475 (in thousands) from $5,546 (in thousands), producing net income of $162,849 (in thousands) versus a net loss of $(34,771) (in thousands). Cash, cash equivalents and marketable securities increased to $849,451 (in thousands), although the quarter's revenue was primarily tied to Takeda opt-out payment recognition rather than reported product sales.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| License and collaboration revenueGAAP | $213,475 (in thousands) | – | – |
| Research and development expenseGAAP | $42,061 (in thousands) | – | – |
| General and administrative expenseGAAP | $12,648 (in thousands) | – | – |
| Total operating expenseGAAP | $54,709 (in thousands) | – | – |
| Income (loss) from operationsGAAP | $158,766 (in thousands) | – | – |
| Interest incomeGAAP | $6,429 (in thousands) | – | – |
| Other (expense) income, netGAAP | $(81) (in thousands) | – | – |
| Income (loss) before income tax expenseGAAP | $165,114 (in thousands) | – | – |
| Income tax expenseGAAP | $2,265 (in thousands) | – | – |
| Net income (loss)GAAP | $162,849 (in thousands) | – | – |
| Net income (loss) per share, basicGAAP | $2.47 | – | – |
| Net income (loss) per share, dilutedGAAP | $2.29 | – | – |
| Weighted-average shares used to compute net income (loss) per share, basicGAAP | 65,935,769 | – | – |
| Weighted-average shares used to compute net income (loss) per share, dilutedGAAP | 71,007,011 | – | – |
| Research and development stock-based compensation expenseGAAP | $7,558 (in thousands) | – | – |
| General and administrative stock-based compensation expenseGAAP | $6,479 (in thousands) | – | – |
| Total stock-based compensation expenseGAAP | $14,037 (in thousands) | – | – |
| Cash, cash equivalents and marketable securitiesother | $849,451 (in thousands) | – | – |
| Working capitalother | 769,967 (in thousands) | – | – |
| Total assetsother | 885,544 (in thousands) | – | – |
| Deferred revenueother | 9,659 (in thousands) | – | – |
| Accumulated deficitother | (304,039) (in thousands) | – | – |
| Total stockholders' equityother | 841,543 (in thousands) | – | – |
second half of 2026 outlook
- Operating expensesWe expect our research and development expenses to increase significantly in the second half of 2026 compared to the first half of 2026.
- NotePN-881 Phase 2 psoriasis program initiation expected in early Q1 2027.
- NoteInitiation of a Phase 1 study with the oral formulation of PN-477 is anticipated in first half of 2027.
- NotePN-458o Phase 1 initiation anticipated in the second half of 2027.
- NotePN-8047 Phase 1 initiation anticipated in Q1 2027.
- NoteRusfertide NDA PDUFA goal date in August 2026.
What drove it
- Second-quarter license and collaboration revenue consisted primarily of $192.4 million related to proportional recognition of the initial $200.0 million opt-out payment received from Takeda.
- Second-quarter license and collaboration revenue included $21.1 million for ongoing development services, including post opt-out wind down services, rusfertide clinical supplies under the Takeda Collaboration Agreement, and other revenues.
- ICOTYDE's FDA approval triggered a $50.0 million milestone earned from JNJ in Q1 2026.
- Research and development expense increased primarily due to clinical development and pre-clinical discovery programs, partially offset by decreases in rusfertide expenses related to the Phase 3 VERIFY clinical trial.
- General and administrative expense increased primarily due to stock-based compensation and other personnel-related expenses.
- The second quarter of 2026 represented ICOTYDE's first full quarter of commercial sales.
Concerns
- Second-quarter license and collaboration revenue was primarily driven by proportional recognition of Takeda's initial $200.0 million opt-out payment.
- The Company expects research and development expenses to increase significantly in the second half of 2026 compared to the first half of 2026.
- Rusfertide remains under FDA Priority Review, with a PDUFA goal date in August 2026.
- Potential collaboration revenue remains dependent on regulatory approvals, sales milestones, and royalties under the Johnson & Johnson and Takeda agreements.
What to watch
- FDA action on rusfertide by the PDUFA goal date in August 2026, including the separate $75 million milestone due upon FDA approval.
- ICOTYDE commercial progress following its first full quarter of commercial sales.
- Initiation of PN-881's comprehensive Phase 2 psoriasis program in early Q1 2027.
- Clinical progress for PN-477sc and anticipated initiation of the oral PN-477 Phase 1 study in first half of 2027.
- Anticipated PN-8047 Phase 1 initiation in Q1 2027 and PN-458o Phase 1 initiation in the second half of 2027.
- Research and development spending in the second half of 2026 as clinical manufacturing, CMC, discovery, headcount, and stock-based compensation investments increase.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $849,451 (in thousands) as of June 30, 2026, compared with $646,002 (in thousands) as of December 31, 2025.
- Working capital was 769,967 (in thousands) as of June 30, 2026, compared with 532,133 (in thousands) as of December 31, 2025.
- Total stockholders' equity was 841,543 (in thousands) as of June 30, 2026, compared with 614,707 (in thousands) as of December 31, 2025.
Analysis
Protagonist recorded license and collaboration revenue of $213,475 (in thousands) in the second quarter of 2026, compared with $5,546 (in thousands) in the second quarter of 2025. The principal contribution was $192.4 million of proportional recognition tied to Takeda's initial $200.0 million rusfertide opt-out payment. The Company also cited $21.1 million from development services, post opt-out wind down services, rusfertide clinical supplies, and other revenues. The release identifies the period as ICOTYDE's first full quarter of commercial sales, but it does not report ICOTYDE sales or royalty revenue.
The revenue increase moved the Company to income from operations of $158,766 (in thousands) and net income of $162,849 (in thousands), compared with an operating loss of $(42,041) (in thousands) and net loss of $(34,771) (in thousands) in the prior-year quarter. Basic earnings were $2.47 per share and diluted earnings were $2.29 per share. The earnings shift principally reflects collaboration-payment recognition, so the composition and recurrence of future collaboration revenue are central to assessing the reported profitability.
Operating investment continued to rise. Research and development expense was $42,061 (in thousands), versus $37,036 (in thousands), while general and administrative expense was $12,648 (in thousands), versus $10,551 (in thousands). Management attributed R&D growth to clinical development and pre-clinical discovery programs, partly offset by lower rusfertide Phase 3 VERIFY costs. It expects R&D expense to increase significantly in the second half of 2026 as PN-881 advances, manufacturing and CMC activities expand, other pipeline programs prepare for clinical work, and headcount and stock-based compensation increase.
Liquidity strengthened, with cash, cash equivalents and marketable securities of $849,451 (in thousands) as of June 30, 2026, compared with $646,002 (in thousands) at December 31, 2025. The near-term catalyst is the FDA's Priority Review of rusfertide, which has a PDUFA goal date in August 2026. Under the Takeda arrangement, FDA approval would trigger a separate $75 million milestone, while Protagonist also disclosed potential future sales milestones and tiered royalties. Pipeline execution is scheduled to broaden with PN-881 Phase 2 initiation expected in early Q1 2027, PN-8047 Phase 1 anticipated in Q1 2027, oral PN-477 Phase 1 anticipated in first half of 2027, and PN-458o Phase 1 anticipated in the second half of 2027.
Management, verbatim
The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner and accelerating momentum across our internal R&D pipeline. ICOTYDE is quickly becoming a paradigm-shifting oral therapy for patients with moderate-to-severe plaque psoriasis, and rusfertide is approaching an FDA decision that could establish it as a first-in-class erythrocytosis targeted medicine for patients with polycythemia vera.
Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist Therapeutics
Not in the filing
stated, not guessed- Gross profit and gross margin.
- Non-GAAP measures, including non-GAAP operating income, net income, and EPS.
- Product sales, ICOTYDE sales, royalty revenue, and reported revenue by operating segment.
- Prior-quarter comparative amounts for quarterly income-statement metrics.
- Percentage year-over-year and quarter-over-quarter changes for reported metrics.
- Operating cash flow, free cash flow, and capital expenditures.
- Debt and other balance-sheet liabilities beyond deferred revenue.
- Share repurchases, dividends, and other capital-return activity.
- Quantitative revenue, gross-margin, tax-rate, or full-year expense guidance.
- Previous-release outlook required to compare reported results with prior guidance.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Protagonist Therapeutics’ SEC Form 8-K (Item 2.02) reporting Q2 2026 financial results and a corporate update on its commercial product ICOTYDE and late-stage rusfertide NDA review status.
Ticker impact
PTGX reported Q2 2026 results and disclosed rusfertide NDA Priority Review with an August 2026 PDUFA decision plus ICOTYDE first full quarter sales.
Bias to upside volatility into the August 2026 PDUFA date, with additional support from the reported cash balance and new milestone/royalty economics.
The filing is a primary-source 8-K with concrete, time-bound regulatory and commercial milestones (Priority Review, PDUFA in August, first full quarter commercial sales) and quantified financial position (cash $849.5M as of June 30, 2026).
Market effects
Reinforces investor focus on oral peptide platforms and late-stage hematology and psoriasis assets with near-term FDA catalysts.
Limited direct regional spillover; primarily US biotech sentiment tied to FDA review timelines.
Takeda and Johnson & Johnson collaboration economics and global commercialization rights can influence broader pharma partnering sentiment.
Counterpoint
Commercial ramp for ICOTYDE is early, and the biggest value driver (rusfertide) remains contingent on FDA outcome despite Priority Review.
Key entities
- companyProtagonist Therapeutics, Inc.
Nasdaq-listed biotech reporting Q2 2026 results, ICOTYDE commercial ramp, and rusfertide NDA Priority Review with August 2026 PDUFA.
- partnerTakeda Pharmaceutical Company
Holds exclusive worldwide development and commercialization rights to rusfertide after Protagonist’s opt-out, with milestone and royalty economics described.
- partnerJohnson & Johnson
Received FDA approval for ICOTYDE, triggering a $50M milestone and supporting Protagonist’s collaboration economics.
- regulatorFDA
Completing review of rusfertide NDA under Priority Review with a PDUFA goal date in August 2026.
